Form 4: AIM ImmunoTech CEO Converts Preferred Stock to Common
Insider Transaction Report
AIM ImmunoTech's CEO, Thomas K. Equels, converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.
Summary
- Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., completed a conversion of preferred stock into common stock.
- On March 12, 2026, 25 shares of Series G Convertible Preferred Stock were converted.
- This conversion resulted in the acquisition of 25,000 shares of AIM ImmunoTech common stock.
- The conversion rate is 1,000 shares of common stock per whole preferred share, effectively valuing the common stock at $1.00 per share.
- Following this transaction, Mr. Equels beneficially owns 63,922 shares of common stock and 0 shares of Series G Convertible Preferred Stock.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO is increasing direct common stock ownership, indicating confidence in the company's future and aligning his interests further with common shareholders.
Positives
- CEO Thomas K. Equels increased his direct beneficial ownership of common stock by 25,000 shares through a conversion, signaling continued confidence in the company.
- The conversion effectively values the common stock at $1.00 per share, which provides a reference point for the insider's valuation of the equity.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider conversions, while not open market purchases, can still signal management's commitment and confidence in the company's long-term prospects by increasing their direct exposure to common equity. This is a standard mechanism for executives to adjust their equity holdings derived from compensation or prior investments.
Stakeholder Impact
- Shareholders: Increased common stock ownership by the CEO may be viewed positively as a sign of confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 03/12/2026 | Conversion of 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock by Thomas K. Equels. |
| 03/16/2026 | Date of filing of the Statement of Changes in Beneficial Ownership (Form 4). |
Keywords
AIM ImmunoTech, AIM, insider transaction, stock conversion, CEO, common stock, preferred stock, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.